الفهرس 
MicroRNA-215 as a diagnostic marker in Egyptian patients with hepatocellular carcinoma
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer worldwide and the third leading cause of cancer-related death. In Egypt, 80% of the patients with hepatocellular carcinoma have underling hepatitis C. MicroRNAs are reported as a group of small non-coding RNAs and aberrant miRNA expression has been reported in HCC patients or cell lines. We aimed to assess diagnostic value of plasma MicroRNA-215 in patients with hepatocellular carcinoma. Methods: A prospective study included 195 subjects divided into 3 groups: healthy controls (group I), Cirrhotic patients (group II), and patients with HCC (group III); all cases were subjected to thorough clinical examination, radiological and laboratory investigations which included quantification of miR-215 by Real- Time qPCR In conclusion, Plasma level of miR-215 might be considered as potential biomarker for diagnosis of HCC. Moreover, miR-215 combined with AFP can be used as a diagnostic biomarker, for early detection of HCC